AGOURA HILLS

ACELYRIN, INC. Announces Leadership Transition

Retrieved on: 
Thursday, May 9, 2024
Corporation, Sale, Zymergen, Graves' ophthalmopathy, Immunotherapy, History, Administration, MRCP, Corporate development, IPO, Patient, Synthetic biology, LOS, SLRN, FRCP, Renewable energy, INC, Knowledge, Aviation, Management

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that ACELYRIN’s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, chief legal and administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company’s Board of Directors (the “Board”).

Key Points: 
  • Ms. Kim brings more than 20 years of operational and leadership experience across a range of industries including synthetic biology, immunotherapy, renewable energy, and aviation.
  • Ms. Kim played a pivotal role in ACELYRIN’s initial public offering and has served as ACELYRIN’s Chief Legal and Administrative Officer since November 2022.
  • “With encouraging data across our pipeline, we are continuing to advance our core mission of making a meaningful difference for patients.
  • The company will file the related quarterly report on Form 10-Q no later than May 14, 2024.

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
Thursday, May 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024

Retrieved on: 
Wednesday, May 8, 2024
Nexus, Nanomedicine, Health, Therapy, Conference, Vaccine, OTCQB

AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference.

Key Points: 
  • AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference.
  • Dr. Andy Hu, Nanomedicine Manager, will be presenting: Nanomedicines: Past, Present, Future.
  • Dr. Hu is an experienced Biomaterial Scientist with expertise in nanomedicine, biologics, vaccines, cell, in vivo, gene therapy, drug development processes.
  • He has great passion for innovative biotherapeutics and leading scientific and technology integration to improve human health.

Joni and Friends debuts the Cub wheelchair to better serve pediatric chair users

Retrieved on: 
Thursday, May 2, 2024
Wheelchair, School, Child, Disability, Cub, Developed country, Prison, Elevator mechanic

We know this because after every Wheels for the World wheelchair outreach, hundreds of people are left still waiting—including children.

Key Points: 
  • We know this because after every Wheels for the World wheelchair outreach, hundreds of people are left still waiting—including children.
  • To meet the growing need for pediatric wheelchairs, Joni and Friends was pleased to help develop a next-generation pediatric mobility device, the Cub wheelchair.
  • Joni and Friends worked with the manufacturer to develop features to better suit the wheelchair for environments in developing nations like narrow doorways, unpaved streets, and small vehicles.
  • Joni and Friends distributes a variety of pediatric wheelchairs through our Wheels for the World outreaches, including restored wheelchairs.

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, IL-17A, Strategic planning, Cell, Exophthalmos, Disease, Infection, Fungus, Risk, Inflammation, SLRN, Patient, Psoriatic arthritis, Acquisition, Doctor of Philosophy, MD, Quality of life, CAS, Senior, IPR, Eye, NeoGenomics, Graves' ophthalmopathy, Suicidal ideation, Behavior, Hidradenitis suppurativa, QW, Drug development, LOS, Corporate communication, Abscess, Diplopia, Pharmaceutical industry

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and highlighted recent corporate updates and upcoming milestones.

Key Points: 
  • R&D Expenses: Research and development expenses were $355.9 million for the full year ended December 31, 2023, as compared to $55.6 million for 2022.
  • G&A Expenses: General and administrative expenses were $66.2 million for the full year ended December 31, 2023, as compared to $13.5 million for 2022.
  • Net Loss: Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022.
  • In December 2023, the Company announced the appointment of Lynn Tetrault to its Board of Directors.

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Monday, March 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Retrieved on: 
Wednesday, March 20, 2024
Oculoplastics, Patient, Private practice, Webcast, TED, Cohort, Standard of care, NEJM, MD, Graves' ophthalmopathy, Hyperglycemia, Safety, Huber loss, Orbital, Medical device

LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

Key Points: 
  • There have been no reports of hyperglycemia or hearing impairment and no serious adverse events.
  • “It is very encouraging to see the results of subcutaneous administration of an anti-IGF-1R therapy.
  • The data shown suggest that there is a clinically meaningful response in patients as early as 3 weeks after a single subcutaneous dose of lonigutamab.
  • “It is important to note that this is preliminary data in a small group, however the positive results are highly promising.

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Retrieved on: 
Monday, March 11, 2024
MACR, Psoriatic arthritis, 1991 World Sportscar Championship, INC, Doctor of Philosophy, LOS, MD, SLRN, ISR, Rheumatology, Skin, Safety, Joint, Swedish Health Services, Enthesitis, Patient, Medicine, HS, LEI, Phase, IL-17A

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.
  • This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.
  • Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F.
  • This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.”

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

Retrieved on: 
Monday, March 11, 2024
Psoriatic arthritis, INC, Doctor of Philosophy, LOS, MD, SLRN, FDA, Quality of life, Pain, Infection, DLQI, Suicidal ideation, Abscess, Risk, Behavior, Safety, Hidradenitis suppurativa, Fungus, Patient, Medicine, IL-17A

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS). These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS).
  • These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.
  • “The magnitude and depth of responses for signs and symptoms of Hidradenitis Suppurativa in this long-term study are consistent with izokibep’s mechanism of action.
  • A confirmatory phase 3 trial of approximately 400 patients is planned to address guidance on size of safety database given the FDA no longer considers moderate-to-severe HS an orphan disease.

Joni and Friends breaks ground on Joni’s House in Serbia

Retrieved on: 
Tuesday, March 5, 2024
Disability, Holden, Hope, Dignity, House, Coffee, Child

On Feb. 29, Joni and Friends executive leadership held a groundbreaking ceremony for a permanent Joni’s House international disability center in Opovo, Serbia, launching a new era of disability ministry in the country.

Key Points: 
  • On Feb. 29, Joni and Friends executive leadership held a groundbreaking ceremony for a permanent Joni’s House international disability center in Opovo, Serbia, launching a new era of disability ministry in the country.
  • Through Joni’s House Serbia, Joni and Friends will work with local partners to provide medical and mobility support, patient advocacy, essential resources and spiritual care to families living with disability.
  • Joni’s House Serbia is the result of two years of meticulous groundwork, including building strong relationships with local partners.
  • Bush, Joni and Friends founder Joni Eareckson Tada was briefed on reports detailing the appalling lack of care for institutionalized children with disabilities in Serbia at the time.